Novel Biomarkers of Subclinical Cardiac Dysfunction in the General Population

Kamal Shemisa, Anish Bhatt, Daniel Cheeran, Ian J. Neeland

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Purpose of Review: Recognition of subclinical myocardial dysfunction offers clinicians and patients an opportunity for early intervention and prevention of symptomatic cardiovascular disease. We review the data on novel biomarkers in subclinical heart disease in the general population with a focus on pathophysiology, recent observational or trial data, and potential applicability and pitfalls for clinical use. Recent Findings: High-sensitivity cardiac troponin and natriuretic peptide assays are powerful markers of subclinical cardiac disease. Elevated levels of these biomarkers signify subclinical cardiac injury and hemodynamic stress and portend an adverse prognosis. Novel biomarkers of myocardial inflammation, fibrosis, and abnormal contraction are gaining momentum as predictors for incident heart failure, providing new insight into pathophysiologic mechanisms of cardiac disease. Summary: There has been exciting growth in both traditional and novel biomarkers of subclinical cardiac injury in recent years. Many biomarkers have demonstrated associations with relevant cardiovascular outcomes and may enhance the diagnostic and prognostic power of more conventional biomarkers. However, their use in “prime time” to identify patients with or at risk for subclinical cardiac dysfunction in the general population remains an open question. Strategic investigation into their clinical applicability in the context of clinical trials remains an area of ongoing investigation.

Original languageEnglish (US)
Pages (from-to)301-310
Number of pages10
JournalCurrent Heart Failure Reports
Volume14
Issue number4
DOIs
StatePublished - Aug 1 2017

Fingerprint

Biomarkers
Population
Heart Diseases
Natriuretic Peptides
Troponin
Wounds and Injuries
Fibrosis
Cardiovascular Diseases
Heart Failure
Hemodynamics
Clinical Trials
Inflammation
Growth

Keywords

  • Biomarkers
  • Cardiac
  • Heart failure
  • Population
  • Subclinical
  • Troponin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Emergency Medicine

Cite this

Novel Biomarkers of Subclinical Cardiac Dysfunction in the General Population. / Shemisa, Kamal; Bhatt, Anish; Cheeran, Daniel; Neeland, Ian J.

In: Current Heart Failure Reports, Vol. 14, No. 4, 01.08.2017, p. 301-310.

Research output: Contribution to journalReview article

Shemisa, Kamal ; Bhatt, Anish ; Cheeran, Daniel ; Neeland, Ian J. / Novel Biomarkers of Subclinical Cardiac Dysfunction in the General Population. In: Current Heart Failure Reports. 2017 ; Vol. 14, No. 4. pp. 301-310.
@article{62a5b7e55cfa4843b9958981d2b15cab,
title = "Novel Biomarkers of Subclinical Cardiac Dysfunction in the General Population",
abstract = "Purpose of Review: Recognition of subclinical myocardial dysfunction offers clinicians and patients an opportunity for early intervention and prevention of symptomatic cardiovascular disease. We review the data on novel biomarkers in subclinical heart disease in the general population with a focus on pathophysiology, recent observational or trial data, and potential applicability and pitfalls for clinical use. Recent Findings: High-sensitivity cardiac troponin and natriuretic peptide assays are powerful markers of subclinical cardiac disease. Elevated levels of these biomarkers signify subclinical cardiac injury and hemodynamic stress and portend an adverse prognosis. Novel biomarkers of myocardial inflammation, fibrosis, and abnormal contraction are gaining momentum as predictors for incident heart failure, providing new insight into pathophysiologic mechanisms of cardiac disease. Summary: There has been exciting growth in both traditional and novel biomarkers of subclinical cardiac injury in recent years. Many biomarkers have demonstrated associations with relevant cardiovascular outcomes and may enhance the diagnostic and prognostic power of more conventional biomarkers. However, their use in “prime time” to identify patients with or at risk for subclinical cardiac dysfunction in the general population remains an open question. Strategic investigation into their clinical applicability in the context of clinical trials remains an area of ongoing investigation.",
keywords = "Biomarkers, Cardiac, Heart failure, Population, Subclinical, Troponin",
author = "Kamal Shemisa and Anish Bhatt and Daniel Cheeran and Neeland, {Ian J.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1007/s11897-017-0342-z",
language = "English (US)",
volume = "14",
pages = "301--310",
journal = "Current Alzheimer Research",
issn = "1531-0035",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Novel Biomarkers of Subclinical Cardiac Dysfunction in the General Population

AU - Shemisa, Kamal

AU - Bhatt, Anish

AU - Cheeran, Daniel

AU - Neeland, Ian J.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Purpose of Review: Recognition of subclinical myocardial dysfunction offers clinicians and patients an opportunity for early intervention and prevention of symptomatic cardiovascular disease. We review the data on novel biomarkers in subclinical heart disease in the general population with a focus on pathophysiology, recent observational or trial data, and potential applicability and pitfalls for clinical use. Recent Findings: High-sensitivity cardiac troponin and natriuretic peptide assays are powerful markers of subclinical cardiac disease. Elevated levels of these biomarkers signify subclinical cardiac injury and hemodynamic stress and portend an adverse prognosis. Novel biomarkers of myocardial inflammation, fibrosis, and abnormal contraction are gaining momentum as predictors for incident heart failure, providing new insight into pathophysiologic mechanisms of cardiac disease. Summary: There has been exciting growth in both traditional and novel biomarkers of subclinical cardiac injury in recent years. Many biomarkers have demonstrated associations with relevant cardiovascular outcomes and may enhance the diagnostic and prognostic power of more conventional biomarkers. However, their use in “prime time” to identify patients with or at risk for subclinical cardiac dysfunction in the general population remains an open question. Strategic investigation into their clinical applicability in the context of clinical trials remains an area of ongoing investigation.

AB - Purpose of Review: Recognition of subclinical myocardial dysfunction offers clinicians and patients an opportunity for early intervention and prevention of symptomatic cardiovascular disease. We review the data on novel biomarkers in subclinical heart disease in the general population with a focus on pathophysiology, recent observational or trial data, and potential applicability and pitfalls for clinical use. Recent Findings: High-sensitivity cardiac troponin and natriuretic peptide assays are powerful markers of subclinical cardiac disease. Elevated levels of these biomarkers signify subclinical cardiac injury and hemodynamic stress and portend an adverse prognosis. Novel biomarkers of myocardial inflammation, fibrosis, and abnormal contraction are gaining momentum as predictors for incident heart failure, providing new insight into pathophysiologic mechanisms of cardiac disease. Summary: There has been exciting growth in both traditional and novel biomarkers of subclinical cardiac injury in recent years. Many biomarkers have demonstrated associations with relevant cardiovascular outcomes and may enhance the diagnostic and prognostic power of more conventional biomarkers. However, their use in “prime time” to identify patients with or at risk for subclinical cardiac dysfunction in the general population remains an open question. Strategic investigation into their clinical applicability in the context of clinical trials remains an area of ongoing investigation.

KW - Biomarkers

KW - Cardiac

KW - Heart failure

KW - Population

KW - Subclinical

KW - Troponin

UR - http://www.scopus.com/inward/record.url?scp=85021110607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021110607&partnerID=8YFLogxK

U2 - 10.1007/s11897-017-0342-z

DO - 10.1007/s11897-017-0342-z

M3 - Review article

VL - 14

SP - 301

EP - 310

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1531-0035

IS - 4

ER -